Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00157105 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery
A Phase 2 study, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT00157105 is a Phase 2 study that has completed, run by Baxalta now part of Shire. The registered enrollment target is 59 participants.
The verdict
NCT00157105, a Phase 2 study, has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A patients undergoing surgery.
Interventions
- DRUG Antihemophilic factor, recombinant, manufactured protein-free
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2001-02-12 |
| Est. Completion | 2004-08-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00157105
The ClinicalTrials.gov registry entry for NCT00157105 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Antihemophilic factor, recombinant, manufactured protein-free is the first listed.
NCT00157105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00157105 about?
NCT00157105 is a clinical study titled "Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery". The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A patients undergoing surgery.
What is the current status of trial NCT00157105?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2001-02-12. Estimated completion is 2004-08-03.
What interventions are being tested in trial NCT00157105?
The interventions under investigation include: Antihemophilic factor, recombinant, manufactured protein-free (DRUG).
Who is sponsoring clinical trial NCT00157105?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.